| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > What Your Employees Won't Tell You - The Number One Secret Revealed |
|
Just Other Articles - What Your Employees Won't Tell You - The Number One Secret Revealed
“If that was the problem, why didn’t she come to me directly?” These are the words of a distraught boss w According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ho lost Sarah, his highest performing sales rep to another company. The reason: more money, more opportun ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ty and extra time off to go to Texas to see her ailing mother. The boss, a hotel owner didn’t want to los lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. Sarah. In fact, he had just invested in sending Sarah to a mandatory training in Atlanta and now he was l here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe sing her. Had he known she was quitting he wouldn’t have sent her to the training. As he scratched his he d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro d wondering why Sarah didn’t approach him before taking another job, the boss made a deal he thought Sarah ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc couldn’t decline: more money, an extra week off and a better office. Of course, he made the offer throug easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi his Sales Director who had to tell the boss the bad news: Sarah declined the new offer. The boss never k nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ew Sarah was lying. Sara didn’t quit because of a better opportunity, she quit because her boss was a jer and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ . Sarah was planning on quitting before she went to Atlanta. In an interview Sarah told me how she felt a ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi out her boss. No one ever got a pat on the back. People were constantly fired without explanation. Ther ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a was no training and no employee hand book. He has no compassion and no one ever knows what to expect. I dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod was miserable working for him and I knew I had to get out. These are words straight from the horse’s mou cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin h…(the horse being Sarah, who is now happily employed elsewhere) with a boss she respects. Sarah’s boss w tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ll never know the truth about why she quit because when you don’t trust someone you won’t be truthful with t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel them. There are about seven things that employees won’t tell their bosses, and the number one thing is th ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust real reason they are quitting. In Gallup poles, research suggests that no other variable directly affect y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products an employee’s productivity than his relationship with his boss. The number one reason an employee quits i . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de because of the direct relationship with his supervisor, and in Sarah’s case, it was her relationship with elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip her boss that tipped her over the edge. When will we catch on that relationships do impact the bottom line tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How to Get a FREE Computer, Scale & Printer from DHL Getting Your Online Health Care Administration Degree Budget Metrics - An Effective Means of Measuring Fiscal Performance
|